Ortho's Renova shows "moderate" improvement for fine wrinkles in 24% of patients treated.
This article was originally published in The Rose Sheet
Executive Summary
ORTHO's RENOVA SHOWS "MODERATE" IMPROVEMENT FOR FINE WRINKLES IN 24% OF PATIENTS treated with the anti-wrinkle agent for 24 weeks compared to 8% of patients using a vehicle emollient cream, according to two clinical trials conducted by the Johnson & Johnson subsidiary. Forty percent of Renova patients compared to 30% of vehicle patients showed a minimal improvement in fine wrinkling and 36% of Renova patients compared to 62% of vehicle patients showed no improvement. Renova was approved on Dec. 29 for the mitigation of fine wrinkles, mottled hyperpigmentation and tactile roughness of facial skin. The antiwrinkle agent will be available by prescription in February.